Department of Pharmaceutical Technology, Faculty of Pharmacy, Near East University, Nicosia, TRNC, Turkey.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey.
Pak J Pharm Sci. 2023 Sep;36(5):1515-1526.
This study aimed to investigate the compressibility properties of Pioglitazone Hydrochloride (PGZ) oral dispersible tablets using a compaction simulator. The tablets were prepared and formulated by direct compression method with varying particle sizes of PGZ in mannitol-based formulations, containing Ludiflash® and its corresponding physical mixture. All formulations were compressed at different compaction forces (5kN-20kN). Powders were evaluated for their tablet properties, such as hardness, friability, disintegration time and dissolution rate. Results showed that all formulations exhibited good compressibility properties. The compaction force and choice of excipient played a vital role in formulation performance and drug release profile. With the use of Minitab 19 an optimized formulation was derived and all predicted outputs was seen to be within range after evaluations. In conclusion, the combined use of the compaction simulator and Minitab 19 were found to be useful tools in predicting the compressibility properties of PGZ and therefore developing a robust oral dispersible tablet. These findings suggest that the compressibility properties of PGZ oral dispersible tablets can be effectively modified by adjusting the critical process parameters (CPP). Hence, providing valuable insights into the compressibility behavior of PGZ oral dispersible tablets and also aiding in the development of optimized tablet formulations.
本研究旨在使用压片机模拟器研究盐酸吡格列酮(PGZ)口服分散片的可压缩性。通过直接压缩法制备和配制了含有基于甘露醇的配方的 PGZ,其中包含 Ludiflash®及其相应的物理混合物,并改变了 PGZ 的颗粒大小。所有配方均在不同的压缩力(5kN-20kN)下进行压缩。粉末的片剂特性,如硬度、脆性、崩解时间和溶出率进行了评估。结果表明,所有配方均表现出良好的可压缩性。压缩力和赋形剂的选择对制剂性能和药物释放特性起着至关重要的作用。使用 Minitab 19 得出了优化的配方,并且在评估后所有预测的输出都在范围内。总之,压片机模拟器和 Minitab 19 的联合使用被发现是预测 PGZ 可压缩性的有用工具,因此可以开发出稳健的口服分散片。这些发现表明,通过调整关键工艺参数(CPP)可以有效改变 PGZ 口服分散片的可压缩性。因此,为 PGZ 口服分散片的可压缩性行为提供了有价值的见解,并有助于优化片剂配方的开发。